|
|
| (36 intermediate revisions by the same user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | {| style="border: 0px; font-size: 85%; margin: 3px; width:600px;" align=center |
| {{Rosuvastatin}}
| | |valign=top| |
| {{CMG}}; {{AE}}
| | |+ |
| | | ! style="background: #4479BA; color:#FFF; width: 100px;" | |
| '''''For patient information about Rosuvastatin, click [[Rosuvastatin (patient information)|here]].'''''
| | ! style="background: #4479BA; color:#FFF; width: 200px;" | |
| | | ! style="background: #4479BA; color:#FFF; width: 250px;" | |
| {{SB}} CRESTOR<sup>®</sup>
| | |- |
| | | | style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | |
| ==Overview==
| | | style="padding: 5px 5px; background: #F5F5F5;" | |
| | | | style="padding: 5px 5px; background: #F5F5F5;" | |
| '''Rosuvastatin''' is a member of the [[medication|drug]] class of [[statin]]s, used to treat [[hypercholesterolemia]] and related conditions, and to prevent [[cardiovascular disease]]. It is currently being marketed by the [[pharmaceutical company]] [[AstraZeneca]] as '''Crestor'''.
| | |} |
| ==Category==
| |
| | |
| Statins,Diols,Carboxylic acids,Sulfonamides,Pyrimidines,Organofluorides,Cardiovasular drugs.
| |
| | |
| ==FDA Package Insert== | |
| ''' [[Rosuvastatin indications and usage|Indications and Usage]]'''
| |
| '''| [[Rosuvastatin dosage and administration|Dosage and Administration]]'''
| |
| '''| [[Rosuvastatin dosage forms and strengths|Dosage Forms and Strengths]]'''
| |
| '''| [[Rosuvastatin contraindications|Contraindications]]'''
| |
| '''| [[Rosuvastatin warnings and precautions|Warnings and Precautions]]'''
| |
| '''| [[Rosuvastatin adverse reactions|Adverse Reactions]]'''
| |
| '''| [[Rosuvastatin drug interactions|Drug Interactions]]'''
| |
| '''| [[Rosuvastatin use in specific populations|Use in Specific Populations]]'''
| |
| '''| [[Rosuvastatin overdosage|Overdosage]]'''
| |
| '''| [[Rosuvastatin description|Description]]'''
| |
| '''| [[Rosuvastatin clinical pharmacology|Clinical Pharmacology]]'''
| |
| '''| [[Rosuvastatin nonclinical toxicology|Nonclinical Toxicology]]'''
| |
| '''| [[Rosuvastatin clinical studies|Clinical Studies]]'''
| |
| '''| [[Rosuvastatin how supplied storage and handling|How Supplied/Storage and Handling]]'''
| |
| '''| [[Rosuvastatin patient counseling information|Patient Counseling Information]]'''
| |
| '''| [[Rosuvastatin labels and packages|Labels and Packages]]'''
| |
| | |
| ==Mechanism of Action== | |
| | |
| CRESTOR is a selective and competitive inhibitor of [[HMG-CoA]] reductase, the rate-limiting enzyme that converts 3‑hydroxy‑3‑methylglutaryl coenzyme A to mevalonate, a precursor of [[cholesterol]]. In vivo studies in animals, and in vitro studies in cultured animal and human cells have shown rosuvastatin to have a high uptake into, and selectivity for, action in the liver, the target organ for [[cholesterol]] lowering. In in vivo and in vitro studies, rosuvastatin produces its lipid-modifying effects in two ways. First, it increases the number of hepatic LDL receptors on the cell-surface to enhance uptake and catabolism of LDL. Second, rosuvastatin inhibits hepatic synthesis of VLDL, which reduces the total number of VLDL and LDL particles.
| |
| ==Interaction with Alcohol==
| |
| | |
| CRESTOR should be used with caution in patients who consume substantial quantities of alcohol and/or have a history of chronic liver disease.Chronic alcohol liver disease is known to increase rosuvastatin exposure.
| |
| ==References==
| |
| {{Reflist|2}}
| |
| | |
| {{Statins}}
| |
| | |
| [[Category:Statins]]
| |
| [[Category:AstraZeneca]]
| |
| [[Category:Carboxylic acids]]
| |
| [[Category:Sulfonamides]]
| |
| [[Category:Pyrimidines]]
| |
| [[Category:Organofluorides]]
| |
| [[Category:Cardiovasular drugs]]
| |
| [[Category:Drugs]]
| |